Search for Clinical Trial Results

Sponsored By

Paraganglioma, Extra-Adrenal - 25 Studies Found

Status Study
Completed Study Name: RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Condition:
  • Pheochromocytoma
  • Extra-adrenal Paraganglioma
  • Extra-Adrenal Paraganglioma
  • Metastatic Adrenal Gland Pheochromo
    Date: 2011-04-21
    Interventions:
    • Other: Laboratory Biomarker Analysis

Completed Study Name: Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
Condition:
  • Childhood Atypical Teratoid/Rhabdoid Tumor
  • Childhood Central Nervous System Choriocarcinoma<
    Date: 2010-02-25
    Interventions:
    • Drug: vorinostat Other Names:
Withdrawn Study Name: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Condition:
  • Phaeochromocytoma
  • Paraganglioma

Date: 2013-09-10
Interventions:
  • Drug: Vandetanib 100 mg, 200 m
Recruiting Study Name: Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Condition:
  • Pheochromocytoma
  • Paraganglioma
  • Inherited Cancer Syndrome Date: 2017-05-05
    Interventions: Genetic: Genetic screening Germline and/or tumor samples will be screened for mutations
Recruiting Study Name: Familial Investigations of Childhood Cancer Predisposition
Condition:
  • Acute Leukemia
  • Adenomatous Polyposis
  • Adrenocortical Carcin
    Date: 2017-02-08
Not yet recruiting Study Name: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Condition:
  • Malignant Adrenal Gland Pheochromocytoma
  • Malignant Paraganglioma
  • Other: Laboratory Biomarker Analysis

Available Study Name: Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Condition:
  • Pheochromocytoma
  • Paraganglioma

Date: 2016-11-08
Interventions: Drug: Ultratrace Iobenguane I131 Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 who
Recruiting Study Name: PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Condition:
  • Neuroendocrine Tumors
  • Carcinoma, Small Cell Lung
  • Carcinoma
    Date: 2016-10-13
    Interventions: Drug: PEN-221 Administration of PEN-221 once every three weeks
Recruiting Study Name: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Condition:
  • Acinar Cell Carcinoma
  • Adrenal Cortex Carcinoma
  • Adrenal Gla
    Date: 2016-07-13
    Interventions:
    • Procedure: Biospecimen Collection

Next >>>